Inclusion Criteria:

          -  Presence of an active hematological malignancy:

               -  Part 1 (Dose Escalation): Diagnosis of B-cell DLBCL, FL, MCL, HL, CLL/SLL, or MM
                  as documented by medical records.

               -  Part 2 (Cohort Expansion): Diagnosis of DLBCL, FL, MCL, HL, CLL/SLL, ALL, MM, or
                  AML as documented in medical records.

          -  Requirement for therapy of the hematological malignancy due to disease-related
             symptoms, lymphadenopathy, organomegaly, extranodal organ involvement, or progressive
             disease.

          -  Hematological malignancy has been previously treated, has relapsed after or progressed
             during prior therapy, and has limited potential for benefit from currently available
             therapy, including hematopoietic stem cell transplantation.

          -  Presence of measurable disease:

               -  For subjects with DLBCL, FL, MCL, HL, or CLL/SLL: presence of radiographically
                  measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the
                  presence of ≥1 lesion that measures ≥2.0 cm in the longest dimension and ≥1.0 cm
                  in the longest perpendicular dimension as assessed by computed tomography).

               -  For subjects with MM, measurable disease with serum monoclonal immunoglobulin
                  protein (M-protein) ≥1 g/dL, or urine M-protein protein ≥200 mg/24 hours, or
                  involved serum free light chain ≥10 mg/dL.

               -  For subjects with ALL or AML, presence of >5% blasts in the bone marrow (based on
                  a bone marrow aspirate/biopsy sample with ≥200 nucleated cells and the presence
                  of bone marrow spicules) and/or >1 x 109/L blasts in the peripheral blood (with
                  the restriction that peripheral blast count in subjects with AML must be <50 x
                  109/L prior to the start of study therapy).

          -  Completion of all previous therapy (including surgery, radiotherapy, chemotherapy,
             immunotherapy, or investigational therapy) for the treatment of cancer ≥2 weeks before
             the start of study therapy. Note: For subjects with AML, the use of hydroxyurea for
             management of leukocytosis is allowed in Cycle 1 if hydroxyurea is started prior to
             the initiation of study therapy.

        Exclusion Criteria:

          -  Part 2 (Cohort Expansion): History of another malignancy except for the following:
             adequately treated local basal cell or squamous cell carcinoma of the skin; adequately
             treated carcinoma in situ without evidence of disease; adequately treated, papillary,
             noninvasive bladder cancer; other adequately treated Stage 1 or 2 cancers currently in
             complete remission; or any other cancer that has been in complete remission for ≥2
             years.

          -  Rapidly progressive, clinically unstable central nervous system hematological
             malignancy. Note: Central nervous system evaluation is only required in subjects with
             known or suspected central nervous system malignancy.

          -  Significant cardiovascular disease, including myocardial infarction, arterial
             thromboembolism, or cerebrovascular thromboembolism, within 6 months prior to start of
             study therapy; symptomatic dysrhythmias or unstable dysrhythmias requiring medical
             therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York
             Heart Association Class 3 or 4 congestive heart failure; uncontrolled Grade ≥3
             hypertension (diastolic blood pressure ≥100 mmHg or systolic blood pressure ≥160 mmHg)
             despite antihypertensive therapy; or history of congenital prolonged QT syndrome.

          -  Significant screening ECG abnormalities, including unstable cardiac arrhythmia
             requiring medication, atrial fibrillation/flutter, left bundle-branch block,
             2nd-degree atrioventricular (AV) block type II, 3rd degree AV block, Grade ≥2
             bradycardia, or QT corrected for heart rate (QTc) >450 msec (for men) or >470 msec
             (for women).

          -  Ongoing risk for bleeding due to active gastrointestinal disease or bleeding
             diathesis.

          -  Evidence of an ongoing systemic bacterial, fungal, or viral infection (including upper
             respiratory tract infections) at the time of start of study therapy. Note: Subjects
             with localized fungal infections of skin or nails are eligible.

          -  In subjects with prior progenitor cell transplantation, evidence of ongoing
             graft-versus-host disease.

        Please speak with Investigator for the complete Inclusion/Exclusion criteria.